Darae Ko

Aug 12, 2024 | jamanetwork.com | Darae Ko |Andrew R. Zullo |Sarah Berry

Antiplatelet and Anticoagulant Use in Nursing Home Residents With Atrial Fibrillation Nursing home (NH) residents are at excess risks of atrial fibrillation (AF)–related stroke and oral anticoagulant (OAC)–related bleeding. In older adults (aged ≥65 years) with multimorbidity and AF, clinicians may select aspirin rather than OAC for stroke prophylaxis to limit bleeding risk.

Mar 15, 2024 | jamanetwork.com | Darae Ko

On July 6, 2023, lecanemab received full approval from the US Food and Drug Administration for the treatment of mild cognitive impairment or early dementia due to Alzheimer disease after the phase 3 CLARITY-AD trial.1 In a population of patients with mild cognitive impairment or early dementia, lecanemab slowed the progression of disability measured with the Clinical Dementia Rating–Sum of Boxes by 27% during 18 months.

Jun 24, 2023 | agsjournals.onlinelibrary.wiley.com | Stephanie Sison |Kueiyu Joshua Lin |Mehdi Najafzadeh |Darae Ko

CLINICAL INVESTIGATION Earlier versions of this work were presented as posters during the 2021 American Geriatric Society Meeting and 2022 Gerontological Society of America Meeting. Abstract Background Among older adults, non-cardiovascular multimorbidity often coexists with cardiovascular disease (CVD) but their clinical significance is uncertain.

Mar 20, 2023 | jamanetwork.com | Kueiyu Joshua Lin |Daniel E. Singer |Darae Ko |Robert J Glynn

Key PointsQuestion  What is the association of frailty level with oral anticoagulant outcomes in terms of home time, clinical events, and total health care costs in patients with atrial fibrillation (AF)? Findings  In this cohort study of 136 551 Medicare beneficiaries with AF, apixaban was associated with increased home time and fewer clinical events than rivaroxaban and warfarin, with greater differences among those with frailty.